Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure

Yamir Reina-Doreste Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Yamir Reina-Doreste in
Current site
Google Scholar
PubMed
Close
 DVM
,
Joshua A. Stern Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Joshua A. Stern in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Bruce W. Keene Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Bruce W. Keene in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Sandra P. Tou Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Sandra P. Tou in
Current site
Google Scholar
PubMed
Close
 DVM
,
Clarke E. Atkins Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Clarke E. Atkins in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Teresa C. DeFrancesco Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Teresa C. DeFrancesco in
Current site
Google Scholar
PubMed
Close
 DVM
,
Marisa K. Ames Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Marisa K. Ames in
Current site
Google Scholar
PubMed
Close
 DVM
,
Timothy E. Hodge Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Timothy E. Hodge in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Kathryn M. Meurs Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.

Search for other papers by Kathryn M. Meurs in
Current site
Google Scholar
PubMed
Close
 DVM, PHD

Abstract

Objective—To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM).

Design—Retrospective case-control study.

Animals—27 cats receiving treatment with pimobendan and 27 cats receiving treatment without pimobendan.

Procedures—Medical records between 2003 and 2013 were reviewed. All cats with HCM or HOCM treated with a regimen that included pimobendan (case cats) were identified. Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. Data collected included signalment, physical examination findings, echocardiographic data, serum biochemical values, and survival time from initial diagnosis of CHF. Kaplan-Meier survival curves were constructed and compared by means of a log rank test.

Results—Cats receiving pimobendan had a significant benefit in survival time. Median survival time of case cats receiving pimobendan was 626 days, whereas median survival time for control cats not receiving pimobendan was 103 days. No significant differences were detected for any other variable.

Conclusions and Clinical Relevance—The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM-affected cats with CHF.

Abstract

Objective—To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM).

Design—Retrospective case-control study.

Animals—27 cats receiving treatment with pimobendan and 27 cats receiving treatment without pimobendan.

Procedures—Medical records between 2003 and 2013 were reviewed. All cats with HCM or HOCM treated with a regimen that included pimobendan (case cats) were identified. Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. Data collected included signalment, physical examination findings, echocardiographic data, serum biochemical values, and survival time from initial diagnosis of CHF. Kaplan-Meier survival curves were constructed and compared by means of a log rank test.

Results—Cats receiving pimobendan had a significant benefit in survival time. Median survival time of case cats receiving pimobendan was 626 days, whereas median survival time for control cats not receiving pimobendan was 103 days. No significant differences were detected for any other variable.

Conclusions and Clinical Relevance—The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM-affected cats with CHF.

  • 1. Boswood A. Current use of pimobendan in canine patients with heart disease. Vet Clin North Am Small Anim Pract 2010; 40: 571580.

  • 2. O'Grady MR, Minors SL, O'Sullivan ML, et al. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med 2008; 22: 897904.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3. Häggström J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008; 22: 11241135.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4. Gordon SG, Miller MW, Saunders AB. Pimobendan in heart failure therapy—a silver bullet? J Am Anim Hosp Assoc 2006; 42: 9093.

  • 5. Smith PJ, French AT, Van Israël N, et al. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005; 46: 121130.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6. Fuentes VL. Use of pimobendan in the management of heart failure. Vet Clin North Am Small Anim Pract 2004; 34: 11451155.

  • 7. Luis Fuentes V, Corcoran B, French A, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 2002; 16: 255261.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 2002; 105: 15031508.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9. Udelson JE, Cannon RO III, Bacharach SL, et al. Beta-adrenergic stimulation with isoproterenol enhances left ventricular diastolic performance in hypertrophic cardiomyopathy despite potentiation of myocardial ischemia. Comparison to rapid atrial pacing. Circulation 1989; 79: 371382.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10. Monrad ES, McKay RG, Baim DS, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984; 70: 10301037.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871878.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12. Asanoi H, Ishizaka S, Kameyama T, et al. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 1994; 23: 268274.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Gordon SG, Saunders AB, Roland RM, et al. Effect of oral administration of pimobendan in cats with heart failure. J Am Vet Med Assoc 2012; 241: 8994.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. Hambrook LE, Bennett PF. Effect of pimobendan on the clinical outcome and survival of cats with non-taurine responsive dilated cardiomyopathy. J Feline Med Surg 2012; 14: 233239.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15. Macgregor JM, Rush JE, Laste NJ, et al. Use of pimobendan in 170 cats (2006–2010). J Vet Cardiol 2011; 13: 251260.

  • 16. Paige CF, Abbott JA, Elvinger F, et al. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc 2009; 234: 13981403.

  • 17. Riesen SC, Kovacevic A, Lombard CW, et al. Prevalence of heart disease in symptomatic cats: an overview from 1998 to 2005. Schweiz Arch Tierheilkd 2007; 149: 6571.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18. Cote E, MacDonald KA, Meurs KM, et al. Hypertrophic cardiomyopathy. In: Cote E, MacDonald KA, Meurs KM, et al, eds. Feline cardiology. Ames, Iowa: Wiley-Blackwell, 2011; 103175.

    • Search Google Scholar
    • Export Citation
  • 19. van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989; 14 (suppl 2): S1S6.

  • 20. Sato N, Asai K, Okumura S, et al. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol 1999; 276:H1699H1705.

    • Search Google Scholar
    • Export Citation
  • 21. Takahashi R, Endoh M. Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. J Cardiovasc Pharmacol 2001; 37: 209218.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22. Shipley EA, Hogan DF, Fiakpui NN, et al. In vitro effect of pimobendan on platelet aggregation in dogs. Am J Vet Res 2013; 74: 403407.

  • 23. Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986; 126: 2130.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24. Fox PR. Feline cardiomyopathies. In: Fox PR, Sisson D, Moise NS, eds. Textbook of canine and feline cardiology. Principles and clinical practice. 2nd ed. Philadelphia: WB Saunders Co, 1999; 621678.

    • Search Google Scholar
    • Export Citation
  • 25. Hanzlicek AS, Gehring R, Kukanich B, et al. Pharmacokinetics in oral pimobendan in healthy cats. J Vet Cardiol 2012; 14: 489496.

  • 26. Hess DR. Retrospective studies and chart reviews. Respir Care 2004; 49: 11711174.

  • 27. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J 2003; 20: 5460.

Advertisement